NASDAQ: SLRX
Salarius Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their SLRX stock forecasts and price targets.

Forecast return on equity

Is SLRX forecast to generate an efficient return?

Forecast return on assets

Is SLRX forecast to generate an efficient return on assets?

SLRX revenue forecast

What is SLRX's revenue in the next 1 years based on estimates from 3 analysts?

Avg 1 year Forecast
$12.1M

SLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SLRX$0.65N/AN/A
JAGX$1.00N/AN/A
MTNB$0.62N/AN/A
GNPX$1.79N/AN/A
OGEN$0.84N/AN/A

Salarius Pharmaceuticals Stock Forecast FAQ

What is SLRX's revenue growth forecast for 2026-2026?

(NASDAQ: SLRX) Salarius Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Salarius Pharmaceuticals's revenue in 2026 is $0.

In 2026, SLRX is forecast to generate $71,008,562 in revenue, with the lowest revenue forecast at $68,224,028 and the highest revenue forecast at $73,095,497.

If you're new to stock investing, here's how to buy Salarius Pharmaceuticals stock.

What is SLRX's forecast return on assets (ROA) for 2026-2026?

(NASDAQ: SLRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 14.36%.

What is SLRX's forecast return on equity (ROE) for 2026-2026?

(NASDAQ: SLRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.